Dicycloverine hydrochloride with alkalis and simeticone oral
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulation of dicycloverine hydrochloride, aluminium hydroxide, light magnesium oxide and simeticone.
Irritable bowel syndrome
10ml to 20ml every 4 hours as required.
Children aged 12 to 18 years: 10ml to 20ml every 4 hours when required.
Children under 12 years
Acute renal failure
Benign prostatic hyperplasia
Chronic renal failure
Severe ulcerative colitis
Precautions and Warnings
Low phosphate diet
Predisposition to glaucoma
Risk of aluminium & magnesium accumulation in renal impairment
Antacids should not be taken at the same time as other drugs
May affect the absorption of concomitant oral drugs
Use with caution in patients with hiatus hernia associated with reflux oesophagitis because anticholinergic drugs may aggravate this condition.
In patients with renal impairment, magnesium salts may cause hypermagnesaemia. Signs of hypermagnesaemia include respiratory depression and loss of deep tendon reflexes due to neuromuscular blockade.
Aluminium hydroxide in patients with low phosphate diets may lead to phosphate deficiency accompanied by increased bone resorption and hypercalciuria with the risk of osteomalacia.
Aluminium hydroxide may be unsafe in patients with porphyria undergoing haemodialysis.
It has been reported that ascorbic acid may enhance aluminium absorption.
Pregnancy and Lactation
Use dicycloverine hydrochloride with alkalis and simeticone as a combined product with caution during pregnancy.
The manufacturer advises that dicycloverine hydrochloride with alkalis and simeticone as a combined product should only be used during pregnancy if treatment is clearly necessary.
Available data following use of dicycloverine hydrochloride in human pregnancy (at doses up to 40mg/day) does not indicate an increased risk of foetal abnormalities if administered during the first trimester of pregnancy.
At the time of writing there is no published data regarding the use of aluminium hydroxide, magnesium oxide and simeticone on exposed pregnancies. Potential risks are unknown.
Use dicycloverine hydrochloride with alkalis and simeticone as a combined product with caution during breastfeeding.
The manufacturer advises caution if dicycloverine is used when breastfeeding as it is not known if it is secreted in human milk.
Available data indicates small amounts of magnesium is expressed in human milk, however any increase in magnesium load to a breast-fed infant is considered unlikely to significantly alter magnesium clearance from the neonate.
Decrease in serum phosphate
Glaucoma (closed angle)
Increased bone resorption
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: May 2020
Summary of Product Characteristics: Kolanticon Gel. Peckforton Pharmaceuticals. Revised February 2020.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 12 May 2020.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.